Cargando…

Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes

PURPOSE: To describe the clinical characteristics and outcomes of myotoxic mushroom poisoning in Thailand. PATIENTS AND METHODS: We performed a retrospective cohort study of cases of myotoxic mushroom poisoning from the Ramathibodi Poison Center Toxic Exposure Surveillance System during a 5-year per...

Descripción completa

Detalles Bibliográficos
Autores principales: Trakulsrichai, Satariya, Jeeratheepatanont, Peerawich, Sriapha, Charuwan, Tongpoo, Achara, Wananukul, Winai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680089/
https://www.ncbi.nlm.nih.gov/pubmed/33235487
http://dx.doi.org/10.2147/IJGM.S271914
_version_ 1783612393821044736
author Trakulsrichai, Satariya
Jeeratheepatanont, Peerawich
Sriapha, Charuwan
Tongpoo, Achara
Wananukul, Winai
author_facet Trakulsrichai, Satariya
Jeeratheepatanont, Peerawich
Sriapha, Charuwan
Tongpoo, Achara
Wananukul, Winai
author_sort Trakulsrichai, Satariya
collection PubMed
description PURPOSE: To describe the clinical characteristics and outcomes of myotoxic mushroom poisoning in Thailand. PATIENTS AND METHODS: We performed a retrospective cohort study of cases of myotoxic mushroom poisoning from the Ramathibodi Poison Center Toxic Exposure Surveillance System during a 5-year period (2012–2016). RESULTS: Forty-one cases were included. Most (53.7%) were male with the average age of 49 years. In three cases, the mushrooms were identified as Russula species by an experienced mycologist. Common presenting symptoms were gastrointestinal (GI) symptoms and myalgia. The median onset of GI symptoms and symptoms suggesting rhabdomyolysis after consuming mushrooms was 2 hours (0.17–24 hours) and 24–48 hours (2–120 hours), respectively. Eight patients who ate the mushrooms together with other patients with rhabdomyolysis had GI symptoms but did not develop rhabdomyolysis. For patients with rhabdomyolysis, acute kidney injury (AKI) and hyperkalaemia occurred in 51.5% and 33.3% of cases, respectively. Median initial and maximum creatine phosphokinase (CPK) levels in patients with rhabdomyolysis were 31,145 and 47,861 U/L, respectively. Fifteen of 17 patients who were investigated for troponin levels had elevated troponin. Three patients had a low ejection fraction. Most patients (95.1%) were admitted to hospital, with a median stay of 5 days. The mortality rate was 26.8%. Treatments included intravenous fluid, urine alkalinization, haemodialysis and peritoneal dialysis. Among patients with rhabdomyolysis, AKI, hyperkalaemia during hospitalisation, maximum CPK level, maximum creatinine level and initial and maximum potassium levels were the factors found to be significantly different between patients who died and those who survived. CONCLUSION: Myotoxic mushroom poisoning had a high mortality rate. Most patients had early or delayed onset of clinical symptoms after mushroom ingestion. Some patients developed severe cardiovascular effects. Early detection, close monitoring (especially serum potassium, creatinine, CPK and cardiac effect) and good supportive care were the main treatment modalities.
format Online
Article
Text
id pubmed-7680089
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76800892020-11-23 Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes Trakulsrichai, Satariya Jeeratheepatanont, Peerawich Sriapha, Charuwan Tongpoo, Achara Wananukul, Winai Int J Gen Med Original Research PURPOSE: To describe the clinical characteristics and outcomes of myotoxic mushroom poisoning in Thailand. PATIENTS AND METHODS: We performed a retrospective cohort study of cases of myotoxic mushroom poisoning from the Ramathibodi Poison Center Toxic Exposure Surveillance System during a 5-year period (2012–2016). RESULTS: Forty-one cases were included. Most (53.7%) were male with the average age of 49 years. In three cases, the mushrooms were identified as Russula species by an experienced mycologist. Common presenting symptoms were gastrointestinal (GI) symptoms and myalgia. The median onset of GI symptoms and symptoms suggesting rhabdomyolysis after consuming mushrooms was 2 hours (0.17–24 hours) and 24–48 hours (2–120 hours), respectively. Eight patients who ate the mushrooms together with other patients with rhabdomyolysis had GI symptoms but did not develop rhabdomyolysis. For patients with rhabdomyolysis, acute kidney injury (AKI) and hyperkalaemia occurred in 51.5% and 33.3% of cases, respectively. Median initial and maximum creatine phosphokinase (CPK) levels in patients with rhabdomyolysis were 31,145 and 47,861 U/L, respectively. Fifteen of 17 patients who were investigated for troponin levels had elevated troponin. Three patients had a low ejection fraction. Most patients (95.1%) were admitted to hospital, with a median stay of 5 days. The mortality rate was 26.8%. Treatments included intravenous fluid, urine alkalinization, haemodialysis and peritoneal dialysis. Among patients with rhabdomyolysis, AKI, hyperkalaemia during hospitalisation, maximum CPK level, maximum creatinine level and initial and maximum potassium levels were the factors found to be significantly different between patients who died and those who survived. CONCLUSION: Myotoxic mushroom poisoning had a high mortality rate. Most patients had early or delayed onset of clinical symptoms after mushroom ingestion. Some patients developed severe cardiovascular effects. Early detection, close monitoring (especially serum potassium, creatinine, CPK and cardiac effect) and good supportive care were the main treatment modalities. Dove 2020-11-17 /pmc/articles/PMC7680089/ /pubmed/33235487 http://dx.doi.org/10.2147/IJGM.S271914 Text en © 2020 Trakulsrichai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Trakulsrichai, Satariya
Jeeratheepatanont, Peerawich
Sriapha, Charuwan
Tongpoo, Achara
Wananukul, Winai
Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
title Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
title_full Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
title_fullStr Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
title_full_unstemmed Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
title_short Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
title_sort myotoxic mushroom poisoning in thailand: clinical characteristics and outcomes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680089/
https://www.ncbi.nlm.nih.gov/pubmed/33235487
http://dx.doi.org/10.2147/IJGM.S271914
work_keys_str_mv AT trakulsrichaisatariya myotoxicmushroompoisoninginthailandclinicalcharacteristicsandoutcomes
AT jeeratheepatanontpeerawich myotoxicmushroompoisoninginthailandclinicalcharacteristicsandoutcomes
AT sriaphacharuwan myotoxicmushroompoisoninginthailandclinicalcharacteristicsandoutcomes
AT tongpooachara myotoxicmushroompoisoninginthailandclinicalcharacteristicsandoutcomes
AT wananukulwinai myotoxicmushroompoisoninginthailandclinicalcharacteristicsandoutcomes